Targeting mechanisms of TGF-β-activation upregulated in FECD may provide a more viable therapeutic strategy to reduce pathological TGF-β-activation while preserving sufficient TGF-β signaling for proper CE function. The gene discussed is TGFB1; the disease is Fuchs endothelial corneal dystrophy.